☆ 4.8 Article

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial

LANCET (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal et al.

Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)

Tatsuya Ioka et al.

Summary: This study demonstrates that adding S-1 to GC can improve overall survival and response rate in patients with advanced biliary tract cancer, making GCS a potential new first-line standard chemotherapy. Additionally, GCS is being tested in a neoadjuvant trial to further evaluate its efficacy.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2023)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina C. Garassino et al.

Summary: This study presents the 5-year outcomes of the KEYNOTE-189 study, which included previously untreated metastatic nonsquamous non-small-cell lung cancer patients. The results show that treatment with pembrolizumab plus pemetrexed-platinum significantly improves overall survival and progression-free survival compared to placebo plus pemetrexed-platinum. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care for previously untreated metastatic non-small-cell lung cancer patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Jean marc Phelip et al.

Summary: This study compared triplet chemotherapy with doublet chemotherapy in advanced biliary tract cancer treatment, with the results showing triplet chemotherapy did not meet the primary study endpoint. Doublet chemotherapy remains the first-line standard in advanced BTC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population

Yasuhisa Ando et al.

Summary: Recent studies have shown the effectiveness of immune checkpoint inhibitors against dMMR/MSI-H cancers. This study investigated the frequency and clinical characteristics of dMMR/MSI-H in BTC patients. Results indicated a 5% frequency of dMMR, with 2 cases exhibiting MSI-H. These findings have important implications for the treatment and prognosis of BTC.

ONCOLOGY LETTERS (2022)

添加到收藏夹

Article Oncology

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer

Yuichiro Doki et al.

Summary: This study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy and durvalumab plus tremelimumab combination therapy in Asian patients with biliary tract cancer, esophageal squamous cell carcinoma, or head and neck squamous cell carcinoma. The results demonstrated acceptable safety profiles and clinical benefit in these patients.

CANCER MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The epidemiological trends of biliary tract cancers in the United States of America

Yong Jiang et al.

Summary: This study provides an overview of the epidemiology of biliary tract cancers (BTCs) based on data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. The study found distinct differences in incidence and mortality rates among different subtypes of BTCs, with intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer (GBC) being the most common and deadliest forms. American Indians and Alaska Natives had the highest incidence rates of GBC, while Asians and Pacific Islanders had the highest incidence rates of ICC, extrahepatic cholangiocarcinoma (ECC), and ampulla of Vater cancer (AVC). Additionally, the incidence rates varied among different age groups.

BMC GASTROENTEROLOGY (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Juan W Valle et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliarytract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo et al.

Summary: The addition of liposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival in advanced biliary tract cancer patients who had progressed on gemcitabine plus cisplatin. Liposomal irinotecan plus fluorouracil and leucovorin could be considered as a standard-of-care second-line therapy for advanced biliary tract cancer, with manageable safety profile.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Oliver Clements et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma

Sylvie Job et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

Longrong Wang et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

C. Morizane et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

Benjamin A. Weinberg et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Ria Winkelmann et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Article Oncology

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Apinya Jusakul et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Review Oncology

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

Andreas R. de Biasi et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Review Immunology

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Laurence Zitvogel et al.

IMMUNITY (2013)

添加到收藏夹

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.